NASDAQ:TCRR TCR2 Therapeutics (TCRR) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.48▼$1.6350-Day Range$1.48▼$1.9852-Week Range$0.82▼$3.88Volume3.91 million shsAverage Volume494,777 shsMarket Capitalization$58.10 millionP/E RatioN/ADividend YieldN/APrice Target$4.91 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability TCR2 Therapeutics MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside232.0% Upside$4.91 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.68) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector196th out of 975 stocksBiological Products, Except Diagnostic Industry26th out of 158 stocks 3.1 Analyst's Opinion Consensus RatingTCR2 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.91, TCR2 Therapeutics has a forecasted upside of 232.0% from its current price of $1.48.Amount of Analyst CoverageTCR2 Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TCRR. Previous Next 0.0 Dividend Strength Dividend YieldTCR2 Therapeutics does not currently pay a dividend.Dividend GrowthTCR2 Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for TCR2 Therapeutics is -0.65. Previous Next N/A News and Social Media Coverage Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TCR2 Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.76% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TCR2 Therapeutics are expected to grow in the coming year, from ($2.68) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTCR2 Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TCR2 Therapeutics (NASDAQ:TCRR) StockTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Read More TCRR Stock News HeadlinesJune 20, 2023 | wsj.comDICE Therapeutics Inc.June 1, 2023 | finance.yahoo.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyOctober 2, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 16, 2023 | benzinga.comTCR2 Therapeutics Insider Trades Send a SignalMay 12, 2023 | msn.comRecap: TCR2 Therapeutics Q1 EarningsMay 11, 2023 | marketwatch.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | finance.yahoo.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 15, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyOctober 2, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>March 25, 2023 | msn.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | finanznachrichten.deTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | msn.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 8, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 6, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | investorplace.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?March 6, 2023 | finanznachrichten.deTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsMarch 6, 2023 | markets.businessinsider.comAdaptimmune To Combine With TCR² In All-stock Deal - Quick FactsMarch 6, 2023 | finance.yahoo.comAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsMarch 6, 2023 | finance.yahoo.comAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsFebruary 16, 2023 | benzinga.comTCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News SummaryFebruary 8, 2023 | finance.yahoo.comTCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023January 18, 2023 | reuters.comTCRR.C - | Stock Price & Latest News | ReutersSee More Headlines Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Company Calendar Last Earnings11/10/2021Today10/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRR CUSIPN/A CIK1750019 Webwww.tcr2.com Phone(617) 949-5200FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.91 High Stock Price Forecast$13.00 Low Stock Price Forecast$1.68 Forecasted Upside/Downside+232.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.81% Return on Assets-69.35% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.57Miscellaneous Outstanding Shares39,260,000Free Float29,443,000Market Cap$58.10 million OptionableNot Optionable Beta1.95 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesGarry E. MenzelPresident, Chief Executive Officer & DirectorPeter OlagunjuChief Operating OfficerEric M. SullivanChief Financial OfficerAlfonso Quintás-CardamaChief Medical OfficerPraveen MalhotraVice President-Information TechnologyKey CompetitorsCardiol TherapeuticsNASDAQ:CRDLOutlook TherapeuticsNASDAQ:OTLKCEL-SCINYSE:CVMDyadic InternationalNASDAQ:DYAIInstil BioNASDAQ:TILView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 100 shares on 8/4/2023Ownership: 0.000%Kevin C TangBought 50,000 shares on 5/25/2023Total: $86,000.00 ($1.72/share)Mpm Asset Management LlcSold 70,170 sharesTotal: $131,919.60 ($1.88/share)Kevin C TangBought 6,183 shares on 5/12/2023Total: $12,056.85 ($1.95/share)Kevin C TangBought 6,774 shares on 5/10/2023Total: $13,209.30 ($1.95/share)View All Insider TransactionsView All Institutional Transactions TCRR Stock - Frequently Asked Questions Should I buy or sell TCR2 Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares. View TCRR analyst ratings or view top-rated stocks. What is TCR2 Therapeutics' stock price forecast for 2023? 7 equities research analysts have issued 1-year price targets for TCR2 Therapeutics' shares. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they predict the company's share price to reach $4.91 in the next year. This suggests a possible upside of 232.0% from the stock's current price. View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts. How were TCR2 Therapeutics' earnings last quarter? TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06. What other stocks do shareholders of TCR2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI). When did TCR2 Therapeutics IPO? (TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. What is TCR2 Therapeutics' stock symbol? TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR." What is TCR2 Therapeutics' stock price today? One share of TCRR stock can currently be purchased for approximately $1.48. How much money does TCR2 Therapeutics make? TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. How many employees does TCR2 Therapeutics have? The company employs 137 workers across the globe. How can I contact TCR2 Therapeutics? TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com. This page (NASDAQ:TCRR) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.